Progenics Pharmaceuticals Submits sNDA For New Delivery System
Progenics Pharmaceuticals and Wyeth Pharmaceuticals, a division of Wyeth, have submitted a supplemental New Drug Application (sNDA) to FDA, and an Extension Application to EU. It is for
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).